In addition to our efforts to maximize the potential impact of DAY101 (tovorafenib), we are in-licensing new compounds that fit our all-ages strategy and capabilities.
Our goal is to better address underserved diseases, extend the duration of therapeutic benefit and achieve long-term durable remission for patients of every age.
Utilizing our broad experience and network of industry, clinical and scientific experts, we’re constantly evaluating additional high-impact programs to further enhance our pipeline for cancer and other life-threatening diseases.
If you have a great development idea, we’d like to hear from you. Contact us at [email protected].
